# Phathom Pharmaceuticals
 (stock symbol: PHAT) Logo in transparent PNG format

## Phathom Pharmaceuticals
 Logo large

### Phathom Pharmaceuticals
 Logo large Download PNG (36 KB)

![Phathom Pharmaceuticals
 Logo large Download PNG (36 KB)](/img/orig/PHAT_BIG-ff99aaea.png)

## Phathom Pharmaceuticals
 Logo icon format

### Phathom Pharmaceuticals
 Logo icon format Download PNG (14.99 KB)

![Phathom Pharmaceuticals
 Logo icon format Download PNG (14.99 KB)](/img/orig/PHAT-acab8a9d.png)

## About Phathom Pharmaceuticals


Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

1. Website domain: phathompharma.com
2. Employees: 77
3. Marketcap: $0.46 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
